BR112022017688A2 - Composições e métodos para dispensação de rna direcionada - Google Patents
Composições e métodos para dispensação de rna direcionadaInfo
- Publication number
- BR112022017688A2 BR112022017688A2 BR112022017688A BR112022017688A BR112022017688A2 BR 112022017688 A2 BR112022017688 A2 BR 112022017688A2 BR 112022017688 A BR112022017688 A BR 112022017688A BR 112022017688 A BR112022017688 A BR 112022017688A BR 112022017688 A2 BR112022017688 A2 BR 112022017688A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- compositions
- dispensation
- targeted rna
- targeted
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 abstract 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- -1 for example Proteins 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Abstract
COMPOSIÇÕES E MÉTODOS PARA DISPENSAÇÃO DE RNA DIRECIONADA. São fornecidas neste documento composições, métodos para fazer as mesmas e métodos para distribuição direcionada de agentes terapêuticos para modificar a expressão e a função de genes alvo, por exemplo, proteínas envolvidas no metabolismo de lipídios e colesterol, como PCSK9. Além disso, são fornecidas neste documento composições e métodos de tratamento de condições relacionadas à doença coronariana.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062984866P | 2020-03-04 | 2020-03-04 | |
US202063078982P | 2020-09-16 | 2020-09-16 | |
PCT/US2021/020955 WO2021178725A1 (en) | 2020-03-04 | 2021-03-04 | Compositions and methods for targeted rna delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022017688A2 true BR112022017688A2 (pt) | 2022-11-16 |
Family
ID=77612786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022017688A BR112022017688A2 (pt) | 2020-03-04 | 2021-03-04 | Composições e métodos para dispensação de rna direcionada |
Country Status (12)
Country | Link |
---|---|
US (3) | US11207416B2 (pt) |
EP (1) | EP4114360A1 (pt) |
JP (1) | JP2023516759A (pt) |
KR (1) | KR20230011913A (pt) |
CN (1) | CN115484932A (pt) |
AU (1) | AU2021230367A1 (pt) |
BR (1) | BR112022017688A2 (pt) |
CA (1) | CA3174708A1 (pt) |
GB (2) | GB2621760A (pt) |
IL (1) | IL296133A (pt) |
MX (1) | MX2022010980A (pt) |
WO (1) | WO2021178725A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021385572A1 (en) | 2020-11-25 | 2023-06-22 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
WO2023015223A2 (en) * | 2021-08-03 | 2023-02-09 | Verve Therapeutics, Inc. | Compositions and methods for targeted rna delivery |
WO2023212622A1 (en) * | 2022-04-26 | 2023-11-02 | University Of Virginia Patent Foundation | SUGAR-CONJUGATED LIPID NANOPARTICLES FOR TARGETED DELIVERY OF siRNA TO HEPATOCYTES |
WO2023220454A1 (en) * | 2022-05-13 | 2023-11-16 | Twister Biotech, Inc. | Conjugated composition and method for delivering a therapeutic nucleic acid sequence to a living cell |
WO2024074666A1 (en) * | 2022-10-06 | 2024-04-11 | Mireca Medicines Gmbh | Conjugates for neuroretinal drug delivery |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009082607A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
SI3431076T1 (sl) * | 2009-06-10 | 2022-04-29 | Arbutus Biopharma Corporation | Izboljšana lipidna formulacija |
WO2011140627A1 (en) * | 2009-11-04 | 2011-11-17 | The University Of British Columbia | Nucleic acid-containing lipid particles and related methods |
US20130202652A1 (en) | 2010-07-30 | 2013-08-08 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
WO2014118272A1 (en) | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
US20140287024A1 (en) * | 2013-03-08 | 2014-09-25 | Shu Wang | Nanoparticle-based delivery system with oxidized phospholipids as targeting ligands for the prevention, diagnosis and treatment of atherosclerosis |
CN112263682A (zh) | 2013-06-27 | 2021-01-26 | 罗氏创新中心哥本哈根有限公司 | 靶向pcsk9的反义寡聚体和缀合物 |
PL3083556T3 (pl) | 2013-12-19 | 2020-06-29 | Novartis Ag | Lipidy i kompozycje lipidowe dla dostarczania środków czynnych |
WO2015113922A1 (en) | 2014-01-30 | 2015-08-06 | Roche Innovation Center Copenhagen A/S | Poly oligomer compound with biocleavable conjugates |
TWI788312B (zh) | 2016-11-23 | 2023-01-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法 |
IL309503A (en) * | 2021-06-24 | 2024-02-01 | Lilly Co Eli | Innovative therapeutic delivery parts and their uses |
-
2021
- 2021-03-04 AU AU2021230367A patent/AU2021230367A1/en active Pending
- 2021-03-04 US US17/192,709 patent/US11207416B2/en active Active
- 2021-03-04 WO PCT/US2021/020955 patent/WO2021178725A1/en unknown
- 2021-03-04 EP EP21764886.4A patent/EP4114360A1/en active Pending
- 2021-03-04 IL IL296133A patent/IL296133A/en unknown
- 2021-03-04 GB GB2317880.9A patent/GB2621760A/en active Pending
- 2021-03-04 KR KR1020227034084A patent/KR20230011913A/ko active Search and Examination
- 2021-03-04 CN CN202180033341.7A patent/CN115484932A/zh active Pending
- 2021-03-04 BR BR112022017688A patent/BR112022017688A2/pt unknown
- 2021-03-04 MX MX2022010980A patent/MX2022010980A/es unknown
- 2021-03-04 CA CA3174708A patent/CA3174708A1/en active Pending
- 2021-03-04 GB GB2213818.4A patent/GB2613225B/en active Active
- 2021-03-04 JP JP2022553596A patent/JP2023516759A/ja active Pending
- 2021-11-23 US US17/533,461 patent/US11801306B2/en active Active
-
2023
- 2023-09-19 US US18/470,280 patent/US20240100169A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4114360A1 (en) | 2023-01-11 |
KR20230011913A (ko) | 2023-01-25 |
US20220152210A1 (en) | 2022-05-19 |
GB2621760A (en) | 2024-02-21 |
MX2022010980A (es) | 2022-12-02 |
GB2613225B (en) | 2024-01-03 |
CN115484932A (zh) | 2022-12-16 |
IL296133A (en) | 2022-11-01 |
JP2023516759A (ja) | 2023-04-20 |
CA3174708A1 (en) | 2021-09-10 |
US11207416B2 (en) | 2021-12-28 |
US20240100169A1 (en) | 2024-03-28 |
GB2613225A (en) | 2023-05-31 |
AU2021230367A1 (en) | 2022-09-29 |
US11801306B2 (en) | 2023-10-31 |
GB202213818D0 (en) | 2022-11-09 |
WO2021178725A1 (en) | 2021-09-10 |
US20210299261A1 (en) | 2021-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022017688A2 (pt) | Composições e métodos para dispensação de rna direcionada | |
CY1125263T1 (el) | Συνθεσεις και μεθοδοι για την αναστολη γονιδιακης εκφρασης της lpa | |
ES2537568T3 (es) | Nuevos fármacos para inhibición de la expresión genética | |
EA202191313A1 (ru) | Композиции на основе липидных наночастиц | |
MX2020003915A (es) | Proteinas trispecificas y metodos de uso. | |
Oliveira et al. | ER stress-inducible factor CHOP affects the expression of hepcidin by modulating C/EBPalpha activity | |
BR112021005769A2 (pt) | proteínas de ligação a dll3 e métodos de uso | |
CY1123485T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπεια νοσων | |
MX2019011004A (es) | Compuestos y composiciones para la administracion intracelular de agentes terapeuticos. | |
SG161267A1 (en) | Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases | |
BR112019009953A2 (pt) | substâncias direcionadas a vários órgãos ou tecidos selecionados | |
Kanazawa et al. | Functional peptide nanocarriers for delivery of novel anti-RelA RNA interference agents as a topical treatment of atopic dermatitis | |
EA201792103A1 (ru) | Композиции и способы для ингибирования экспрессии генов hif2альфа | |
Chaudhary et al. | Deciphering the roles of trehalose and Hsp104 in the inhibition of aggregation of mutant huntingtin in a yeast model of Huntington’s disease | |
BR112022020795A2 (pt) | Métodos para edição alvejada de um ácido ribonucleico alvo e para prevenir ou tratar síndrome de hurler, ácido ribonucleico de recrutamento da adenosina desaminase engenheirado, construção, e, composição, lipossoma, exossoma, nanopartícula de lipídeo, célula, biblioteca ou kit | |
CR20240003A (es) | Restos de administración terapéutica novedosos y usos de estos | |
Hasan et al. | The novel functional nucleic acid iRed effectively regulates target genes following cytoplasmic delivery by faint electric treatment | |
BR112013002945A2 (pt) | composição farmacâutica formulada com agente de eco-contraste de microbolhas e um ácido nucleico terapêutico de interesse para uso em um método para tratamento de uma doença ocular em um sujeito | |
PA8683901A1 (es) | Amidas sustituidas con heteroarilo que comprenden un grupo enlazador saturado, y su uso como agentes farmacéuticos | |
BR112018010736A2 (pt) | oligonucleotídeos antissenso contra il-34 e métodos de uso dos mesmos | |
Iwata et al. | Synthesis and properties of vitamin E analog-conjugated neomycin for delivery of RNAi drugs to liver cells | |
BR112023020490A2 (pt) | Composições e métodos para expressão de transgenes oculares | |
BR112022009254A2 (pt) | Agentes antissenso il-34 e métodos de usar os mesmos | |
GT200600210A (es) | Terapia genica de interferon-beta usdando un sistema mejorado de expresion regulada | |
BR112022005028A2 (pt) | Molécula de ácido nucleico para tratamento de trombocitopenia e uso da mesma |